Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications:where do we stand?
作者机构：Clinical PharmacyUmm Al-Qura UniversityMakkahSaudi Arabia School of PharmacyUniversity of BirminghamBirminghamUK
出 版 物：《General Psychiatry》 (综合精神医学（英文）)
年 卷 期：2021年第34卷第4期
页 面：69-73页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：This study was funded by the University of Birmingham
主 题：medication metabolism cardiovascular
摘 要：INTRODUCTION Despite the known benefits of antipsychotic medications,they have been associated with increased risks of cardiometabolic side ***-induced adverse cardiometabolic effects,such as weight gain,high blood pressure,alterations in glucose metabolism and lipid dysregulation,are well-recognised risk factors for cardiovascular diseases(CVDs)and diabetes.1 Clinical guidelines call for regular physical health assessments and laboratory monitoring as a means to prevent and detect adverse cardiometabolic effects of antipsychotic ***,recent evidence suggests that cardiovascular condi-tions remain the key causes of death among people using antipsychotic medications,suggesting suboptimal screening and moni-toring *** cardiometabolic screening among antipsychotic users can hinder the early detection of high-risk people and delay receiving proper management.
维普期刊数据库